Inflammation, fracture and bone repair

Bone

Volumn 86, Issue , 2016, Pages 119-130

  Loi, Florence ^a   Córdova, Luis A ^a,b   Pajarinen, Jukka ^a   Lin, Tzu hua ^a   Yao, Zhenyu ^a   Goodman, Stuart B ^a,c  

^a STANFORD UNIVERSITY   (United States)

^b UNIVERSITY OF CHILE   (Chile)

^c Stanford University   (United States)

Author keywords

Bone repair; Fracture healing; Inflammation; Tissue engineering

Indexed keywords

OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B;

BONE CELL; BONE REGENERATION; BONE REMODELING; CELL INTERACTION; FRACTURE; FRACTURE HEALING; FRACTURE NONUNION; FRAGILITY FRACTURE; HUMAN; INFLAMMATION; INFLAMMATORY CELL; MACROPHAGE; MESENCHYMAL STEM CELL; MOLECULAR MECHANICS; MONOCYTE; NEUTROPHIL; NONHUMAN; OSSIFICATION; OSTEOCLAST; OSTEOLYSIS; REVIEW; ANIMAL; CELL COMMUNICATION; OSTEOCYTE; PATHOLOGY;

ANIMALS; CELL COMMUNICATION; FRACTURE HEALING; FRACTURES, BONE; HUMANS; INFLAMMATION; OSTEOCYTES;

EID: 84960875945     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2016.02.020     Document Type: Review

References (189)

1. Miranda M.A., Moon M.S. Treatment strategy for nonunions and malunions. Surgical Treatment of Orthopaedic Trauma 2007, 77-100. Thieme, New York. J.P. Stannard, A.H. Schmidt, P.J. Kregor (Eds.).
2. Hak D.J., Fitzpatrick D., Bishop J.A., Marsh J.L., Tilp S., Schnettler R., Simpson H., Alt V. Delayed union and nonunions: epidemiology, clinical issues, and financial aspects. Injury 2014, 45(Suppl. 2):S3-S7.
3. What is Osteoporosis? 2015, National Osteoporosis Foundation.
4. Jahangir A.A., Nunley R.M., Mehta S., Sharan A., Fellows T.W.H.P. Bone-graft substitutes in orthopaedic surgery. AAOS Now 2008, 2:1-5.
5. Department of Research & Scientific Affairs AAoOS Annual Incidence of Common Musculoskeletal Procedures and Treatment 2014.
6. Mountziaris P.M., Spicer P.P., Kasper F.K., Mikos A.G. Harnessing and modulating inflammation in strategies for bone regeneration. Tissue Eng. B Rev. 2011, 17:393-402.
7. Marsell R., Einhorn T.A. The biology of fracture healing. Injury 2011, 42:551-555.
8. Nich C., Takakubo Y., Pajarinen J., Ainola M., Salem A., Sillat T., Rao A.J., Raska M., Tamaki Y., Takagi M., Konttinen Y.T., Goodman S.B., Gallo J. Macrophages-key cells in the response to wear debris from joint replacements. J. Biomed. Mater. Res. A 2013, 101:3033-3045.
9. Mosser D.M., Edwards J.P. Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 2008, 8:958-969.
10. Mantovani A., Biswas S.K., Galdiero M.R., Sica A., Locati M. Macrophage plasticity and polarization in tissue repair and remodelling. J. Pathol. 2013, 229:176-185.
11. Kawai T., Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 2011, 34:637-650.
12. Ortega-Gomez A., Perretti M., Soehnlein O. Resolution of inflammation: an integrated view. EMBO Mol. Med. 2013, 5:661-674.
13. Kumagai K., Vasanji A., Drazba J.A., Butler R.S., Muschler G.F. Circulating cells with osteogenic potential are physiologically mobilized into the fracture healing site in the parabiotic mice model. J. Orthop. Res. 2008, 26:165-175.
14. Fong E.L., Chan C.K., Goodman S.B. Stem cell homing in musculoskeletal injury. Biomaterials 2011, 32:395-409.
15. Osta B., Benedetti G., Miossec P. Classical and paradoxical effects of TNF-a on bone homeostasis. Front. Immunol. 2014, 5:1-9.
16. Giannoudis P.V., Einhorn T.A., Marsh D. Fracture healing: the diamond concept. Injury 2007, 38(Suppl. 4):S3-S6.
17. Jagodzinski M., Krettek C. Effect of mechanical stability on fracture healing-an update. Injury 2007, 38(Suppl. 1):S3-10.
18. Claes L., Recknagel S., Ignatius A. Fracture healing under healthy and inflammatory conditions. Nat. Rev. Rheumatol. 2012, 8:133-143.
19. McKibbin B. The biology of fracture healing in long bones. J. Bone Joint Surg. (Br.) 1978, 60-B:150-162.
20. Perren S.M. Physical and biological aspects of fracture healing with special reference to internal fixation. Clin. Orthop. Relat. Res. 1979, 175-96.
21. Shapiro F. Cortical bone repair. the relationship of the lacunar-canalicular system and intercellular gap junctions to the repair process. J. Bone Joint Surg. Am. 1988, 70:1067-1081.
22. Perren S.M. Evolution of the internal fixation of long bone fractures. the scientific basis of biological internal fixation: choosing a new balance between stability and biology. J. Bone Joint Surg. (Br.) 2002, 84:1093-1110.
23. Harwood P.J., Newman J.B., Michael A.L.R. An update on fracture healing and non-union. J. Orthop. Trauma 2010, 24:9-23.
24. Gerstenfeld L.C., Cullinane D.M., Barnes G.L., Graves D.T., Einhorn T.A. Fracture healing as a post-natal developmental process: molecular, spatial, and temporal aspects of its regulation. J. Cell. Biochem. 2003, 88:873-884.
25. Uhthoff H.K., Rahn B.A. Healing patterns of metaphyseal fractures. Clin. Orthop. Relat. Res. 1981, 295-303.
26. Aspenberg P., Sandberg O. Distal radial fractures heal by direct woven bone formation per Aspenberg and Olof Sandberg. Acta Orthop. 2013, 84:297-300.
27. Chen W.T., Han da C., Zhang P.X., Han N., Kou Y.H., Yin X.F., Jiang B.G. A special healing pattern in stable metaphyseal fractures. Acta Orthop. 2015, 86:238-242.
28. Claes L., Reusch M., Gockelmann M., Ohnmacht M., Wehner T., Amling M., Beil F.T., Ignatius A. Metaphyseal fracture healing follows similar biomechanical rules as diaphyseal healing. J. Orthop. Res. 2011, 29:425-432.
29. Kolar P., Schmidt-Bleek K., Schell H., Gaber T., Toben D., Schmidmaier G., Perka C., Buttgereit F., Duda G.N. The early fracture hematoma and its potential role in fracture healing. Tissue Eng. B Rev. 2010, 16:427-434.
30. Grundnes O., Reikeras O. The importance of the hematoma for fracture healing in rats. Acta Orthop. Scand. 1993, 64:340-342.
31. Park S.H., Silva M., Bahk W.J., McKellop H., Lieberman J.R. Effect of repeated irrigation and debridement on fracture healing in an animal model. J. Orthop. Res. 2002, 20:1197-1204.
32. Gerstenfeld L.C., Cho T.J., Kon T., Aizawa T., Cruceta J., Graves B.D., Einhorn T.A. Impaired intramembranous bone formation during bone repair in the absence of tumor necrosis factor-alpha signaling. Cells Tissues Organs 2001, 169:285-294.
33. Gerstenfeld L.C., Cho T.J., Kon T., Aizawa T., Tsay A., Fitch J., Barnes G.L., Graves D.T., Einhorn T.A. Impaired fracture healing in the absence of TNF-alpha signaling: the role of TNF-alpha in endochondral cartilage resorption. J. Bone Miner. Res. 2003, 18:1584-1592.
34. Yang X., Ricciardi B.F., Hernandez-Soria A., Shi Y., Pleshko Camacho N., Bostrom M.P. Callus mineralization and maturation are delayed during fracture healing in interleukin-6 knockout mice. Bone 2007, 41:928-936.
35. Glass G.E., Chan J.K., Freidin A., Feldmann M., Horwood N.J., Nanchahal J. TNF-alpha promotes fracture repair by augmenting the recruitment and differentiation of muscle-derived stromal cells. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:1585-1590.
36. Bastian O., Pillay J., Alblas J., Leenen L., Koenderman L., Blokhuis T. Systemic inflammation and fracture healing. J. Leukoc. Biol. 2011, 89:669-673.
37. Xing Z., Lu C., Hu D., Yu Y.Y., Wang X., Colnot C., Nakamura M., Wu Y., Miclau T., Marcucio R.S. Multiple roles for CCR2 during fracture healing. Dis. Model. Mech. 2010, 3:451-458.
38. Hurst S.M., Wilkinson T.S., McLoughlin R.M., Jones S., Horiuchi S., Yamamoto N., Rose-John S., Fuller G.M., Topley N., Jones S.A. Il-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity 2001, 14:705-714.
39. Alexander K.A., Chang M.K., Maylin E.R., Kohler T., Muller R., Wu A.C., Van Rooijen N., Sweet M.J., Hume D.A., Raggatt L.J., Pettit A.R. Osteal macrophages promote in vivo intramembranous bone healing in a mouse tibial injury model. J. Bone Miner. Res. 2011, 26:1517-1532.
40. Raggatt L.J., Wullschleger M.E., Alexander K.A., Wu A.C., Millard S.M., Kaur S., Maugham M.L., Gregory L.S., Steck R., Pettit A.R. Fracture healing via periosteal callus formation requires macrophages for both initiation and progression of early endochondral ossification. Am. J. Pathol. 2014, 184:3192-3204.
41. Pettit A.R., Chang M.K., Hume D.A., Raggatt L.J. Osteal macrophages: a new twist on coupling during bone dynamics. Bone 2008, 43:976-982.
42. Kon T., Cho T.J., Aizawa T., Yamazaki M., Nooh N., Graves D., Gerstenfeld L.C., Einhorn T.A. Expression of osteoprotegerin, receptor activator of NF-kappaB ligand (osteoprotegerin ligand) and related proinflammatory cytokines during fracture healing. J. Bone Miner. Res. 2001, 16:1004-1014.
43. Bielby R., Jones E., McGonagle D. The role of mesenchymal stem cells in maintenance and repair of bone. Injury 2007, 38(Suppl. 1):S26-S32.
44. Wu A.C., Raggatt L.J., Alexander K.A., Pettit A.R. Unraveling macrophage contributions to bone repair. Bonekey Rep. 2013, 2:373.
45. Xu L., Li G. Circulating mesenchymal stem cells and their clinical implications. J. Orthop. Transl. 2014, 2:1-7.
46. Tsiridis E., Upadhyay N., Giannoudis P. Molecular aspects of fracture healing: which are the important molecules?. Injury 2007, 38(Suppl. 1):S11-S25.
47. Schindeler A., McDonald M.M., Bokko P., Little D.G. Bone remodeling during fracture repair: the cellular picture. Semin. Cell Dev. Biol. 2008, 19:459-466.
48. Grundnes O., Reikeras O. Blood flow and mechanical properties of healing bone. Femoral osteotomies studied in rats. Acta Orthop. Scand. 1992, 63:487-491.
49. Melnyk M., Henke T., Claes L., Augat P. Revascularisation during fracture healing with soft tissue injury. Arch. Orthop. Trauma Surg. 2008, 128:1159-1165.
50. Keramaris N.C., Calori G.M., Nikolaou V.S., Schemitsch E.H., Giannoudis P.V. Fracture vascularity and bone healing: a systematic review of the role of VEGF. Injury 2008, 39(Suppl. 2):S45-S57.
51. Thompson Z., Miclau T., Hu D., Helms J.A. A model for intramembranous ossification during fracture healing. J. Orthop. Res. 2002, 20:1091-1098.
52. Malizos K.N., Papatheodorou L.K. The healing potential of the periosteum molecular aspects. Injury 2005, 36(Suppl. 3):S13-S19.
53. Gaston M.S., Simpson A.H. Inhibition of fracture healing. J. Bone Joint Surg. (Br.) 2007, 89:1553-1560.
54. Komatsu D.E., Warden S.J. The control of fracture healing and its therapeutic targeting: improving upon nature. J. Cell. Biochem. 2010, 109:302-311.
55. Serhan C.N., Savill J. Resolution of inflammation: the beginning programs the end. Nat. Immunol. 2005, 6:1191-1197.
56. O'Keefe R.J., Mao J. Bone tissue engineering and regeneration: from discovery to the clinic-an overview. Tissue Eng. B Rev. 2011, 17:389-392.
57. Mountziaris P.M., Mikos A.G. Modulation of the inflammatory response for enhanced bone tissue regeneration. Tissue Eng. B Rev. 2008, 14:179-186.
58. Waters R.V., Gamradt S.C., Asnis P., Vickery B.H., Avnur Z., Hill E., Bostrom M. Systemic corticosteroids inhibit bone healing in a rabbit ulnar osteotomy model. Acta Orthop. Scand. 2000, 71:316-321.
59. Arron J.R., Choi Y. Bone versus immune system. Nature 2000, 408:535-536.
60. Arboleya L., Castañeda S. Osteoimmunology: the study of the relationship between the immune system and bone tissue. Reumatol. Clin. 2013, 9:303-315.
61. Takayanagi H. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat. Rev. Immunol. 2007, 7:292-304.
62. Walsh M.C., Kim N., Kadono Y., Rho J., Lee S.Y., Lorenzo J., Choi Y. Osteoimmunology: interplay between the immune system and bone metabolism. Annu. Rev. Immunol. 2006, 24:33-63.
63. Konnecke I., Serra A., El Khassawna T., Schlundt C., Schell H., Hauser A., Ellinghaus A., Volk H.D., Radbruch A., Duda G.N., Schmidt-Bleek K. T and B cells participate in bone repair by infiltrating the fracture callus in a two-wave fashion. Bone 2014, 64:155-165.
64. Criscitiello C., Viale G., Gelao L., Esposito A., De Laurentiis M., De Placido S., Santangelo M., Goldhirsch A., Curigliano G. Crosstalk between bone niche and immune system: osteoimmunology signaling as a potential target for cancer treatment. Cancer Treat. Rev. 2015, 41:61-68.
65. Greenblatt M.B., Shim J.H. Osteoimmunology: a brief introduction. Immune. Netw. 2013, 13:111-115.
66. Kovach T.K., Dighe A.S., Lobo P.I., Cui Q. Interactions between MSCs and immune cells: implications for bone healing. Int. J. Immunol. Res. 2015, 2015:752510.
67. Shi C., Pamer E.G. Monocyte recruitment during infection and inflammation. Nat. Rev. Immunol. 2011, 11:762-774.
68. Brown B.N., Ratner B.D., Goodman S.B., Amar S., Badylak S.F. Macrophage polarization: an opportunity for improved outcomes in biomaterials and regenerative medicine. Biomaterials 2012, 33:3792-3802.
69. Martinez F.O., Sica A., Mantovani A., Locati M. Macrophage activation and polarization. Front. Biosci. 2008, 13:453-461.
70. Spiller K.L., Nassiri S., Witherel C.E., Anfang R.R., Ng J., Nakazawa K.R., Yu T., Vunjak-Novakovic G. Sequential delivery of immunomodulatory cytokines to facilitate the M1-to-M2 transition of macrophages and enhance vascularization of bone scaffolds. Biomaterials 2015, 37:194-207.
71. da Silva Meirelles L., Chagastelles P.C., Nardi N.B. Mesenchymal stem cells reside in virtually all post-natal organs and tissues. J. Cell Sci. 2006, 119:2204-2213.
72. Harada S., Rodan G.A. Control of osteoblast function and regulation of bone mass. Nature 2003, 423:349-355.
73. Nakashima K., Zhou X., Kunkel G., Zhang Z., Deng J.M., Behringer R.R., de Crombrugghe B. The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell 2002, 108:17-29.
74. Marie P.J., Kassem M. Osteoblasts in osteoporosis: past, emerging, and future anabolic targets. Eur. J. Endocrinol. 2011, 165:1-10.
75. Bellido T. Osteocyte-driven bone remodeling. Calcif. Tissue Int. 2014, 94:25-34.
76. Boyle W.J., Simonet W.S., Lacey D.L. Osteoclast differentiation and activation. Nature 2003, 423:337-342.
77. Khosla S. Minireview: the OPG/RANKL/RANK system. Endocrinology 2001, 142:5050-5055.
78. Yasuda H., Shima N., Nakagawa N., Yamaguchi K., Kinosaki M., Mochizuki S., Tomoyasu A., Yano K., Goto M., Murakami A., Tsuda E., Morinaga T., Higashio K., Udagawa N., Takahashi N., Suda T. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:3597-3602.
79. Takayanagi H., Ogasawara K., Hida S., Chiba T., Murata S., Sato K., Takaoka A., Yokochi T., Oda H., Tanaka K., Nakamura K., Taniguchi T. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature 2000, 408:600-605.
80. Takayanagi H. Inflammatory bone destruction and osteoimmunology. J. Periodontal Res. 2005, 40:287-293.
81. Lee S.K., Lorenzo J. Cytokines regulating osteoclast formation and function. Curr. Opin. Rheumatol. 2006, 18:411-418.
82. Takayanagi H. Osteoimmunology and the effects of the immune system on bone. Nat. Rev. Rheumatol. 2009, 5:667-676.
83. Aliprantis A.O., Ueki Y., Sulyanto R., Park A., Sigrist K.S., Sharma S.M., Ostrowski M.C., Olsen B.R., Glimcher L.H. NFATc1 in mice represses osteoprotegerin during osteoclastogenesis and dissociates systemic osteopenia from inflammation in cherubism. J. Clin. Invest. 2008, 118:3775-3789.
84. Locksley R.M., Killeen N., Lenardo M.J. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001, 104:487-501.
85. Takahashi N., Mundy G.R., Roodman G.D. Recombinant human interferon-gamma inhibits formation of human osteoclast-like cells. J. Immunol. 1986, 137:3544-3549.
86. Chang M.K., Raggatt L.J., Alexander K.A., Kuliwaba J.S., Fazzalari N.L., Schroder K., Maylin E.R., Ripoll V.M., Hume D.A., Pettit A.R. Osteal tissue macrophages are intercalated throughout human and mouse bone lining tissues and regulate osteoblast function in vitro and in vivo. J. Immunol. 2008, 181:1232-1244.
87. Hoch A.I., Binder B.Y., Genetos D.C., Leach J.K. Differentiation-dependent secretion of proangiogenic factors by mesenchymal stem cells. PLoS One 2012, 7.
88. Porter J.R., Ruckh T.T., Popat K.C. Bone tissue engineering: a review in bone biomimetics and drug delivery strategies. Biotechnol. Prog. 2009, 25:1539-1560.
89. Anton K., Banerjee D., Glod J. Macrophage-associated mesenchymal stem cells assume an activated, migratory, pro-inflammatory phenotype with increased IL-6 and CXCL10 secretion. PLoS One 2012, 7.
90. Freytes D.O., Kang J.W., Marcos-Campos I., Vunjak-Novakovic G. Macrophages modulate the viability and growth of human mesenchymal stem cells. J. Cell. Biochem. 2013, 114:220-229.
91. Champagne C.M., Takebe J., Offenbacher S., Cooper L.F. Macrophage cell lines produce osteoinductive signals that include bone morphogenetic protein-2. Bone 2002, 30:26-31.
92. Fromigue O., Marie P.J., Lomri A. Bone morphogenetic protein-2 and transforming growth factor-beta2 interact to modulate human bone marrow stromal cell proliferation and differentiation. J. Cell. Biochem. 1998, 68:411-426.
93. Blom A.B., van Lent P.L., Holthuysen A.E., van der Kraan P.M., Roth J., van Rooijen N., van den Berg W.B. Synovial lining macrophages mediate osteophyte formation during experimental osteoarthritis. Osteoarthr. Cartil. 2004, 12:627-635.
94. Vi L., Baht G.S., Whetstone H., Ng A., Wei Q., Poon R., Mylvaganam S., Grynpas M., Alman B.A. Macrophages promote osteoblastic differentiation in-vivo: implications in fracture repair and bone homeostasis. J. Bone Miner. Res. 2015, 30:1090-1102.
95. Nicolaidou V., Wong M.M., Redpath A.N., Ersek A., Baban D.F., Williams L.M., Cope A.P., Horwood N.J. Monocytes induce STAT3 activation in human mesenchymal stem cells to promote osteoblast formation. PLoS One 2012, 7.
96. Guihard P., Boutet M.A., Brounais-Le Royer B., Gamblin A.L., Amiaud J., Renaud A., Berreur M., Redini F., Heymann D., Layrolle P., Blanchard F. Oncostatin m, an inflammatory cytokine produced by macrophages, supports intramembranous bone healing in a mouse model of tibia injury. Am. J. Pathol. 2015, 185:765-775.
97. Chen Z., Wu C., Gu W., Klein T., Crawford R., Xiao Y. Osteogenic differentiation of bone marrow MSCs by beta-tricalcium phosphate stimulating macrophages via BMP2 signalling pathway. Biomaterials 2014, 35:1507-1518.
98. Lorenzo J. Interactions between immune and bone cells: new insights with many remaining questions. J. Clin. Invest. 2000, 106:749-752.
99. Gilbert L., He X., Farmer P., Boden S., Kozlowski M., Rubin J., Nanes M.S. Inhibition of osteoblast differentiation by tumor necrosis factor-alpha. Endocrinology 2000, 141:3956-3964.
100. Cavagis A., Takamori E., Granjeiro J., Oliveira R., Ferreira C., Peppelenbosch M., Zambuzzi W. TNFalpha contributes for attenuating both Y397FAK and Y416Src phosphorylations in osteoblasts. Oral Dis. 2014, 20:780-786.
101. Ding J., Ghali O., Lencel P., Broux O., Chauveau C., Devedjian J.C., Hardouin P., Magne D. TNF-alpha and IL-1beta inhibit RUNX2 and collagen expression but increase alkaline phosphatase activity and mineralization in human mesenchymal stem cells. Life Sci. 2009, 84:499-504.
102. Guo R., Yamashita M., Zhang Q., Zhou Q., Chen D., Reynolds D.G., Awad H.A., Yanoso L., Zhao L., Schwarz E.M., Zhang Y.E., Boyce B.F., Xing L. Ubiquitin ligase Smurf1 mediates tumor necrosis factor-induced systemic bone loss by promoting proteasomal degradation of bone morphogenetic signaling proteins. J. Biol. Chem. 2008, 283:23084-23092.
103. Lange J., Sapozhnikova A., Lu C., Hu D., Li X., Miclau T., Marcucio R.S. Action of IL-1beta during fracture healing. J. Orthop. Res. 2010, 28:778-784.
104. Miller R.R., Cappola A.R., Shardell M.D., Hawkes W.G., Yu-Yahiro J.A., Hebel J.R., Magaziner J. Persistent changes in interleukin-6 and lower extremity function following hip fracture. J. Gerontol. A Biol. Sci. Med. Sci. 2006, 61:1053-1058.
105. Caparbo V.F., Prada F., Silva C.A., Regio P.L., Pereira R.M. Serum from children with polyarticular juvenile idiopathic arthritis (pJIA) inhibits differentiation, mineralization and may increase apoptosis of human osteoblasts "in vitro". Clin. Rheumatol. 2009, 28:71-77.
106. Hofbauer L.C., Lacey D.L., Dunstan C.R., Spelsberg T.C., Riggs B.L., Khosla S. Interleukin-1beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone 1999, 25:255-259.
107. Lam J., Takeshita S., Barker J.E., Kanagawa O., Ross F.P., Teitelbaum S.L. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J. Clin. Invest. 2000, 106:1481-1488.
108. Jimi E., Nakamura I., Duong L.T., Ikebe T., Takahashi N., Rodan G.A., Suda T. Interleukin 1 induces multinucleation and bone-resorbing activity of osteoclasts in the absence of osteoblasts/stromal cells. Exp. Cell Res. 1999, 247:84-93.
109. Tan S.D., Kuijpers-Jagtman A.M., Semeins C.M., Bronckers A.L., Maltha J.C., Von den Hoff J.W., Everts V., Klein-Nulend J. Fluid shear stress inhibits TNFalpha-induced osteocyte apoptosis. J. Dent. Res. 2006, 85:905-909.
110. Mori G., D'Amelio P., Faccio R., Brunetti G. The interplay between the bone and the immune system. Clin. Dev. Immunol. 2013, 2013:720504.
111. Girasole G., Jilka R.L., Passeri G., Boswell S., Boder G., Williams D.C., Manolagas S.C. 17 beta-estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: a potential mechanism for the antiosteoporotic effect of estrogens. J. Clin. Invest. 1992, 89:883-891.
112. Grogaard B., Gerdin B., Reikeras O. The polymorphonuclear leukocyte: has it a role in fracture healing?. Arch. Orthop. Trauma Surg. 1990, 109:268-271.
113. Toben D., Schroeder I., El Khassawna T., Mehta M., Hoffmann J.E., Frisch J.T., Schell H., Lienau J., Serra A., Radbruch A., Duda G.N. Fracture healing is accelerated in the absence of the adaptive immune system. J. Bone Miner. Res. 2011, 26:113-124.
114. Martin P., D'Souza D., Martin J., Grose R., Cooper L., Maki R., McKercher S.R. Wound healing in the PU.1 null mouse-tissue repair is not dependent on inflammatory cells. Curr. Biol. 2003, 13:1122-1128.
115. Kim J., Hematti P. Mesenchymal stem cell-educated macrophages: a novel type of alternatively activated macrophages. Exp. Hematol. 2009, 37:1445-1453.
116. Arai F., Hirao A., Ohmura M., Sato H., Matsuoka S., Takubo K., Ito K., Koh G.Y., Suda T. Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche. Cell 2004, 118:149-161.
117. Calvi L.M., Adams G.B., Weibrecht K.W., Weber J.M., Olson D.P., Knight M.C., Martin R.P., Schipani E., Divieti P., Bringhurst F.R., Milner L.A., Kronenberg H.M., Scadden D.T. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 2003, 425:841-846.
118. Kollet O., Dar A., Shivtiel S., Kalinkovich A., Lapid K., Sztainberg Y., Tesio M., Samstein R.M., Goichberg P., Spiegel A., Elson A., Lapidot T. Osteoclasts degrade endosteal components and promote mobilization of hematopoietic progenitor cells. Nat. Med. 2006, 12:657-664.
119. Rao M., Supakorndej T., Schmidt A.P., Link D.C. Osteoclasts are dispensable for hematopoietic progenitor mobilization by granulocyte colony-stimulating factor in mice. Exp. Hematol. 2015, 43:110-114. (e1-2).
120. Charles J.F., Aliprantis A.O. Osteoclasts: more than 'bone eaters'. Trends Mol. Med. 2014, 20:449-459.
121. Cho D.I., Kim M.R., Jeong H.Y., Jeong H.C., Jeong M.H., Yoon S.H., Kim Y.S., Ahn Y. Mesenchymal stem cells reciprocally regulate the M1/M2 balance in mouse bone marrow-derived macrophages. Exp. Mol. Med. 2014, 46.
122. Ren G., Zhang L., Zhao X., Xu G., Zhang Y., Roberts A.I., Zhao R.C., Shi Y. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2008, 2:141-150.
123. Nakajima H., Uchida K., Guerrero A.R., Watanabe S., Sugita D., Takeura N., Yoshida A., Long G., Wright K.T., Johnson W.E., Baba H. Transplantation of mesenchymal stem cells promotes an alternative pathway of macrophage activation and functional recovery after spinal cord injury. J. Neurotrauma 2012, 29:1614-1625.
124. Maggini J., Mirkin G., Bognanni I., Holmberg J., Piazzon I.M., Nepomnaschy I., Costa H., Canones C., Raiden S., Vermeulen M., Geffner J.R. Mouse bone marrow-derived mesenchymal stromal cells turn activated macrophages into a regulatory-like profile. PLoS One 2010, 5.
125. Prockop D.J. Concise review: two negative feedback loops place mesenchymal stem/stromal cells at the center of early regulators of inflammation. Stem Cells 2013, 31:2042-2046.
126. Gómez-Barrena E., Rosset P., Lozano D., Stanovici J., Ermthaller C., Gerbhard F. Bone fracture healing: cell therapy in delayed unions and nonunions. Bone 2015, 70:93-101.
127. Goodman S.B., Gibon E., Pajarinen J., Lin T.H., Keeney M., Ren P.G., Nich C., Yao Z., Egashira K., Yang F., Konttinen Y.T. Novel biological strategies for treatment of wear particle-induced periprosthetic osteolysis of orthopaedic implants for joint replacement. J. R. Soc. Interface 2014, 11.
128. Córdova L.A., Trichet V., Escriou V., Rosset P., Amiaud J., Battaglia S., Charrier C., Berreur M., Brion R., Gouin F., Layrolle P., Passuti N., Heymann D. Inhibition of osteolysis and increase of bone formation after local administration of siRNA-targeting RANK in a polyethylene particle-induced osteolysis model. Acta Biomater. 2015, 13:150-158.
129. Heymann D. Bisphosphonates and bone diseases: past, present and future. Curr. Pharm. Des. 2010, 16:2948-2949.
130. Nardi A., Ventura L., Cozzi L., Tonini G., Zennaro R., Celi M., Ramazzina E. The bone anabolic therapy. Aging Clin. Exp. Res. 2013, 25:121-124.
131. Andrews E.B., Gilsenan A.W., Midkiff K., Sherrill B., Wu Y., Mann B.H., Masica D. The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years. J. Bone Miner. Res. 2012, 27:2429-2437.
132. Allen M.R. Bisphosphonates and osteonecrosis of the jaw: moving from the bedside to the bench. Cells Tissues Organs 2009, 189:289-294.
133. Carvalho N.N.C., Voss L.A., Almeida M.O.P., Salgado C.L., Bandeira F. Atypical femoral fractures during prolonged use of bisphosphonates: short-term responses to strontium ranelate and teriparatide. J. Clin. Endocrinol. Metab. 2011, 96:2675-2680.
134. Simon L.S. Osteoporosis. Rheum. Dis. Clin. N. Am. 2007, 33:149-176.
135. Simpson A.H., Murray I.R. Osteoporotic fracture models. Curr. Osteoporos. Rep. 2015, 13:9-15.
136. Silverman S.L., Siris E., Kendler D.L., Belazi D., Brown J.P., Gold D.T., Lewiecki E.M., Papaioannou A., Simonelli C., Ferreira I., Balasubramanian A., Dakin P., Ho P., Siddhanti S., Stolshek B., Recknor C. Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study. Osteoporos. Int. 2015, 26:361-372.
137. Pietschmann P., Mechtcheriakova D., Meshcheryakova A., Foger-Samwald U., Ellinger I. Immunology of osteoporosis: a mini-Review. Gerontology 2015.
138. Franceschi C., Bonafe M., Valensin S., Olivieri F., De Luca M., Ottaviani E., De Benedictis G. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann. N. Y. Acad. Sci. 2000, 908:244-254.
139. Lencel P., Magne D. Inflammaging: the driving force in osteoporosis?. Med. Hypotheses 2011, 76:317-321.
140. Topini C., Topini D., Cerica G., Nardocci F., Topini G. Osteoporosis and risk of fracture, analysis on a population admitted in rehabilitation post-acute. Clin. Cases Miner. Bone Metab. 2014, 11:129-131.
141. Perren S.M. Fracture healing: fracture healing understood as the result of a fascinating cascade of physical and biological interactions. Part I. An attempt to integrate observations from 30 years AO research. Acta Chir. Orthop. Traumatol. Cech. 2014, 81:355-364.
142. Donoso O., Pino A.M., Seitz G., Osses N., Rodriguez J.P. Osteoporosis-associated alteration in the signalling status of BMP-2 in human MSCs under adipogenic conditions. J. Cell. Biochem. 2015.
143. Coughlan T., Dockery F. Osteoporosis and fracture risk in older people. Clin. Med. 2014, 14:187-191.
144. Ibrahim N., Khamis M.F., Mod Yunoh M.F., Abdullah S., Mohamed N., Shuid A.N. Targeted delivery of lovastatin and tocotrienol to fracture site promotes fracture healing in osteoporosis model: micro-computed tomography and biomechanical evaluation. PLoS One 2014, 9.
145. Nikolaou V.S., Efstathopoulos N., Kontakis G., Kanakaris N.K., Giannoudis P.V. The influence of osteoporosis in femoral fracture healing time. Injury 2009, 40:663-668.
146. Panteli M., Pountos I., Jones E., Giannoudis P.V. Biological and molecular profile of fracture non-union tissue: current insights. J. Cell. Mol. Med. 2015, 19:685-713.
147. Copuroglu C., Calori G.M., Giannoudis P.V. Fracture non-union: who is at risk?. Injury 2013, 44:1379-1382.
148. Behrens A., van Deursen J.M., Rudolph K.L., Schumacher B. Impact of genomic damage and ageing on stem cell function. Nat. Cell Biol. 2014, 16:201-207.
149. Iwakura T., Miwa M., Sakai Y., Niikura T., Lee S.Y., Oe K., Hasegawa T., Kuroda R., Fujioka H., Doita M., Kurosaka M. Human hypertrophic nonunion tissue contains mesenchymal progenitor cells with multilineage capacity in vitro. J. Orthop. Res. 2009, 27:208-215.
150. Kloen P., Doty S.B., Gordon E., Rubel I.F., Goumans M.J., Helfet D.L. Expression and activation of the BMP-signaling components in human fracture nonunions. J. Bone Joint Surg. Am. 2002, 84-A:1909-1918.
151. Qu G., von Schroeder H.P. The osteogenic potential of pseudoarthrosis tissue and bone from human scaphoid non-unions. J. Hand Surg. Eur. Vol. 2008, 33:449-456.
152. Fernandez-Bances I., Perez-Basterrechea M., Perez-Lopez S., Nunez Batalla D., Fernandez Rodriguez M.A., Alvarez-Viejo M., Ferrero-Gutierrez A., Menendez-Menendez Y., Garcia-Gala J.M., Escudero D., Paz Aparicio J., Carnero Lopez S., Lopez Fernandez P., Gonzalez Suarez D., Otero Hernandez J. Repair of long-bone pseudoarthrosis with autologous bone marrow mononuclear cells combined with allogenic bone graft. Cytotherapy 2013, 15:571-577.
153. Hisatome T., Yasunaga Y., Yanada S., Tabata Y., Ikada Y., Ochi M. Neovascularization and bone regeneration by implantation of autologous bone marrow mononuclear cells. Biomaterials 2005, 26:4550-4556.
154. Seita J., Weissman I.L. Hematopoietic stem cell: self-renewal versus differentiation. Wiley Interdiscip. Rev. Syst. Biol. Med. 2010, 2:640-653.
155. Hernigou P., Poignard A., Manicom O., Mathieu G., Rouard H. The use of percutaneous autologous bone marrow transplantation in nonunion and avascular necrosis of bone. J. Bone Joint Surg. (Br.) 2005, 87:896-902.
156. Patterson T.E., Kumagai K., Griffith L., Muschler G.F. Cellular strategies for enhancement of fracture repair. J. Bone Joint Surg. Am. 2008, 90(Suppl. 1):111-119.
157. Lin T.H., Tamaki Y., Pajarinen J., Waters H.A., Woo D.K., Yao Z., Goodman S.B. Chronic inflammation in biomaterial-induced periprosthetic osteolysis: NF-kappaB as a therapeutic target. Acta Biomater. 2014, 10:1-10.
158. Branemark R., Branemark P.I., Rydevik B., Myers R.R. Osseointegration in skeletal reconstruction and rehabilitation: a review. J. Rehabil. Res. Dev. 2001, 38:175-181.
159. Anderson J.M., Rodriguez A., Chang D.T. Foreign body reaction to biomaterials. Semin. Immunol. 2008, 20:86-100.
160. Trindade R., Albrektsson T., Tengvall P., Wennerberg A. Foreign body reaction to biomaterials: on mechanisms for buildup and breakdown of osseointegration. Clin. Implant. Dent. Relat. Res. 2016, (18):192-203.
161. Albrektsson T., Dahlin C., Jemt T., Sennerby L., Turri A., Wennerberg A. Is marginal bone loss around oral implants the result of a provoked foreign body reaction?. Clin. Implant. Dent. Relat. Res. 2014, 16:155-165.
162. Sundfeldt M., Carlsson L.V., Johansson C.B., Thomsen P., Gretzer C. Aseptic loosening, not only a question of wear: a review of different theories. Acta Orthop. 2006, 77:177-197.
163. Albrektsson T., Dahl E., Enbom L., Engevall S., Engquist B., Eriksson A.R., Feldmann G., Freiberg N., Glantz P.O., Kjellman O., et al. Osseointegrated oral implants. A Swedish multicenter study of 8139 consecutively inserted nobelpharma implants. J. Periodontol. 1988, 59:287-296.
164. Papaspyridakos P., Mokti M., Chen C.J., Benic G.I., Gallucci G.O., Chronopoulos V. Implant and prosthodontic survival rates with implant fixed complete dental prostheses in the edentulous mandible after at least 5 years: a systematic review. Clin. Implant. Dent. Relat. Res. 2014, 16:705-717.
165. Zwartele R.E., Witjes S., Doets H.C., Stijnen T., Poll R.G. Cementless total hip arthroplasty in rheumatoid arthritis: a systematic review of the literature. Arch. Orthop. Trauma Surg. 2012, 132:535-546.
166. Gallo J., Raska M., Konttinen Y.T., Nich C., Goodman S.B. Innate immunity sensors participating in pathophysiology of joint diseases: a brief overview. J. Long-Term Eff. Med. Implants 2014, 24:297-317.
167. Gallo J., Vaculova J., Goodman S.B., Konttinen Y.T., Thyssen J.P. Contributions of human tissue analysis to understanding the mechanisms of loosening and osteolysis in total hip replacement. Acta Biomater. 2014, 10:2354-2366.
168. Pajarinen J., Jamsen E., Konttinen Y.T., Goodman S.B. Innate immune reactions in septic and aseptic osteolysis around hip implants. J. Long-Term Eff. Med. Implants 2014, 24:283-296.
169. Zhang X., Morham S.G., Langenbach R., Young D.A., Xing L., Boyce B.F., Puzas E.J., Rosier R.N., O'Keefe R.J., Schwarz E.M. Evidence for a direct role of cyclo-oxygenase 2 in implant wear debris-induced osteolysis. J. Bone Miner. Res. 2001, 16:660-670.
170. Childs L.M., Goater J.J., O'Keefe R.J., Schwarz E.M. Efficacy of etanercept for wear debris-induced osteolysis. J. Bone Miner. Res. 2001, 16:338-347.
171. Gibon E., Ma T., Ren P.G., Fritton K., Biswal S., Yao Z., Smith L., Goodman S.B. Selective inhibition of the MCP-1-CCR2 ligand-receptor axis decreases systemic trafficking of macrophages in the presence of UHMWPE particles. J. Orthop. Res. 2012, 30:547-553.
172. Keeney M., Waters H., Barcay K., Jiang X., Yao Z., Pajarinen J., Egashira K., Goodman S.B., Yang F. Mutant MCP-1 protein delivery from layer-by-layer coatings on orthopedic implants to modulate inflammatory response. Biomaterials 2013, 34:10287-10295.
173. Lin T.H., Sato T., Barcay K.R., Waters H., Loi F., Zhang R., Pajarinen J., Egashira K., Yao Z., Goodman S.B. NF-kappaB decoy oligodeoxynucleotide enhanced osteogenesis in mesenchymal stem cells exposed to polyethylene particle. Tissue Eng. A 2015, 21:875-883.
174. Beane O.S., Fonseca V.C., Cooper L.L., Koren G., Darling E.M. Impact of aging on the regenerative properties of bone marrow-, muscle-, and adipose-derived mesenchymal stem/stromal cells. PLoS One 2014, 9.
175. Rao A.J., Nich C., Dhulipala L.S., Gibon E., Valladares R., Zwingenberger S., Smith R.L., Goodman S.B. Local effect of IL-4 delivery on polyethylene particle induced osteolysis in the murine calvarium. J. Biomed. Mater. Res. A 2013, 101:1926-1934.
176. Pajarinen J., Kouri V.P., Jamsen E., Li T.F., Mandelin J., Konttinen Y.T. The response of macrophages to titanium particles is determined by macrophage polarization. Acta Biomater. 2013, 9:9229-9240.
177. Pajarinen J., Tamaki Y., Antonios J.K., Lin T.H., Sato T., Yao Z., Takagi M., Konttinen Y.T., Goodman S.B. Modulation of mouse macrophage polarization in vitro using IL-4 delivery by osmotic pumps. J. Biomed. Mater. Res. A 2015, 103:1339-1345.
178. Pirris S.M., Nottmeier E.W., Kimes S., O'Brien M., Rahmathulla G. A retrospective study of iliac crest bone grafting techniques with allograft reconstruction: do patients even know which iliac crest was harvested? Clinical article. J. Neurosurg. Spine 2014, 21:595-600.
179. Grayson W.L., Frohlich M., Yeager K., Bhumiratana S., Chan M.E., Cannizzaro C., Wan L.Q., Liu X.S., Guo X.E., Vunjak-Novakovic G. Engineering anatomically shaped human bone grafts. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:3299-3304.
180. Jing W., Smith A.A., Liu B., Li J., Hunter D.J., Dhamdhere G., Salmon B., Jiang J., Cheng D., Johnson C.A., Chen S., Lee K., Singh G., Helms J.A. Reengineering autologous bone grafts with the stem cell activator WNT3A. Biomaterials 2015, 47:29-40.
181. Kanczler J.M., Oreffo R.O. Osteogenesis and angiogenesis: the potential for engineering bone. Eur. Cell. Mater. 2008, 15:100-114.
182. Wang M., Zhang G., Wang Y., Liu T., Zhang Y., An Y., Li Y. Crosstalk of mesenchymal stem cells and macrophages promotes cardiac muscle repair. Int. J. Biochem. Cell Biol. 2015, 58:53-61.
183. Spiller K.L., Anfang R.R., Spiller K.J., Ng J., Nakazawa K.R., Daulton J.W., Vunjak-Novakovic G. The role of macrophage phenotype in vascularization of tissue engineering scaffolds. Biomaterials 2014, 35:4477-4488.
184. Spiller K.L., Vunjak-Novakovic G. Clinical translation of controlled protein delivery systems for tissue engineering. Drug Deliv. Transl. Res. 2015, 5:101-115.
185. Wernike E., Montjovent M.O., Liu Y., Wismeijer D., Hunziker E.B., Siebenrock K.A., Hofstetter W., Klenke F.M. VEGF incorporated into calcium phosphate ceramics promotes vascularisation and bone formation in vivo. Eur. Cell. Mater. 2010, 19:30-40.
186. Aro H.T., Govender S., Patel A.D., Hernigou P., Perera de Gregorio A., Popescu G.I., Golden J.D., Christensen J., Valentin A. Recombinant human bone morphogenetic protein-2: a randomized trial in open tibial fractures treated with reamed nail fixation. J. Bone Joint Surg. Am. 2011, 93:801-808.
187. Das A., Tanner S., Barker D.A., Green D., Botchwey E.A. Delivery of S1P receptor-targeted drugs via biodegradable polymer scaffolds enhances bone regeneration in a critical size cranial defect. J. Biomed. Mater. Res. A 2014, 102:1210-1218.
188. Kaplan J.M., Youd M.E., Lodie T.A. Immunomodulatory activity of mesenchymal stem cells. Curr. Stem Cell Res. Ther. 2011, 6:297-316.
189. Mikita J., Dubourdieu-Cassagno N., Deloire M.S., Vekris A., Biran M., Raffard G., Brochet B., Canron M.H., Franconi J.M., Boiziau C., Petry K.G. Altered M1/M2 activation patterns of monocytes in severe relapsing experimental rat model of multiple sclerosis. Amelioration of clinical status by M2 activated monocyte administration. Mult. Scler. 2011, 17:2-15.